On Thursday, January 10, 2019 at 7:30am Pacific Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities at the 37th Annual J.P. Morgan Healthcare Conference.
More Information
We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.
Our Science
We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.
Learn MoreImmunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.
